Vireo Growth (VREOF) Enterprise Value (2020 - 2026)
Vireo Growth's (VREOF) quarterly Enterprise Value came in at -$123.4 million in Q1 2026, down 40.3% year-on-year from -$206.7 million in Q1 2025, and little changed quarter-over-quarter from -$123.5 million in Q4 2025.
Vireo Growth (VREOF) Enterprise Value (2020 - 2026) Analysis & Trends
Vireo Growth has disclosed Enterprise Value across 7 years of filings, most recently posting -$123.4 million for Q1 2026.
- Enterprise Value for Q1 2026 came in at -$123.4 million, down 40.3% year-over-year; the trailing twelve-month figure through Mar 2026 was -$123.4 million (down 40.3% YoY), and the FY2025 annual result was -$123.5 million, down 31.56% from the prior year.
- Enterprise Value came in at -$123.4 million for Q1 2026 at Vireo Growth, roughly flat from -$123.5 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$7.3 million in Q3 2024 to a low of -$123.5 million in Q4 2025.
- The 5-year median for Enterprise Value is -$17.0 million (2022), against an average of -$47.1 million.
- Across the five-year window, Enterprise Value jumped 78.79% in 2022 and slumped 1528.49% in 2025, its largest moves.
- Vireo Growth's Enterprise Value stood at -$15.1 million in 2022, then declined by 18.17% to -$17.9 million in 2023, then sank by 424.36% to -$93.9 million in 2024, then plunged by 31.56% to -$123.5 million in 2025, then gained by 0.08% to -$123.4 million in 2026.
- The last three Enterprise Value figures came in at -$123.4 million (Q1 2026), -$123.5 million (Q4 2025), and -$118.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | -3.74 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -1.94 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -2.15 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | -77.77 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -1.32 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -428.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -511.86 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -750.88 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | -498.58 Mn |
| 10 | Vireo Growth | - | - | 59.30 Mn | -123.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -123.40 Mn |
| Dec 31, 2025 | -123.50 Mn |
| Sep 30, 2025 | -118.55 Mn |
| Jun 30, 2025 | -107.19 Mn |
| Mar 31, 2025 | -87.95 Mn |
| Dec 31, 2024 | -93.87 Mn |
| Sep 30, 2024 | -7.28 Mn |
| Jun 30, 2024 | -11.23 Mn |
| Mar 31, 2024 | -12.60 Mn |
| Dec 31, 2023 | -17.90 Mn |
| Sep 30, 2023 | -13.30 Mn |
| Jun 30, 2023 | -11.35 Mn |
| Mar 31, 2023 | -10.35 Mn |
| Dec 31, 2022 | -15.15 Mn |
| Sep 30, 2022 | -21.84 Mn |
| Jun 30, 2022 | -16.97 Mn |
| Mar 31, 2022 | -8.60 Mn |
| Dec 31, 2021 | -15.16 Mn |
| Sep 30, 2021 | -11.78 Mn |
| Jun 30, 2021 | -20.83 Mn |